Mitochondrial diseases are a heterogeneous group of disorders affecting energy production in the human body. The diagnosis of mitochondrial diseases represents a challenge to clinicians, especially for pediatric cases, which show enormous variation in clinical presentations, as well as biochemical and genetic complexity.
Introduction
Mitochondrial disease (MD) was first introduced in 1962, when a group of investigators, Luft et al 1 , described a young Swedish woman with severe nonthyroid origin hypermetabolism. In 1963, Engel and Cunningham 2 used a modification of the Gomori trichrome stain that allowed for the detection of abnormal mitochondrial proliferation in muscle as irregular purplish patches in fibers that were dubbed "ragged red fibers (RRFs)". Since then, there has been great interest in the diagnosis of mitochondrial diseases (MDs). The diagnosis of MD can be traced back to the premolecular era, 1962e1988, when MDs were defined on the basis of clinical examination, muscle biopsy, and biochemical criteria. In the molecular era, the full complexity of these disorders became evident.
MDs are a heterogeneous group of disorders affecting energy production in the human body, which can occur with a probable frequency in preschool children (age < 6 years) of approximately 1 in 11,000, 3 and the minimum birth prevalence for respiratory chain disorders with onset at any age was estimated at 1 in 7634. 4 MDs may present at any age with a spectrum of symptoms and signs spanning a number of medical specialties. As cells with high energy requirements, such as neurons, skeletal and cardiac muscle, are particularly vulnerable to limited adenosine triphosphate (ATP) supply, encephalopathy and myopathy are often prominent features in various mitochondrial phenotypes. Enzymes involved in mitochondrial energy production are coded by two genomes (mitochondrial and nuclear) in the organism. Due to their clinical, biochemical, and genetic complexity, MDs represent a challenge to clinicians, especially for pediatric cases, which show enormous variation in clinical presentations and course.
In Taiwan, the first clinical MD was reported in 1988, 5 and the first mitochondrial DNA (mtDNA) mutation was identified in 1992. 6 Many cases have since been reported in pediatric groups. 7e47 Although MDs are being diagnosed more frequently, clinical physicians still find diagnosis a challenge because clinical symptoms/signs evolve over time and the number of genes known to be involved in mitochondrial energy production continues to increase.
The purpose of this study is to review the molecular classification scheme and associated phenotypes in infants and children with MDs, in addition to providing an overview of the basic biochemical reactions and genetic characteristics in the mitochondrion, clinical manifestations, and diagnostic methods. A diagnostic algorithm for identifying MDs in pediatric neurology patients is proposed. Figure 1 Metabolic pathways in mitochondrion. ADP Z adenosine diphosphate; ATP Z adenosine triphosphate; CACT Z carnitineeacylcarnitine translocase; CoQ Z coenzyme Q; CPT Z carnitine palmitoyltransferase; Cyta Z cytochrome a; Cytb Z cytochrome b; Cytc Z cytochrome c; DIC Z dicarboxylate carrier; FAD Z flavin adenine dinucleotide; FeS Z iron sulfur protein; FMN Z flavin mononucleotide; NADH Z nicotinamide adenine dinucleotide; PC Z pyruvate carboxylase; PDHC Z pyruvate dehydrogenase complex; TCA Z tricarboxylic acid. 
Biochemical reactions in the mitochondrion
The mitochondrion, an extranuclear organelle, is 0.5e1 mm in size. It consists of outer and inner membranes, an intermembranous space, and an inner matrix compartment. The matrix contains various enzymes, ribosomes, transfer RNAs (tRNAs), and mtDNA molecules. Each cell contains many mitochondria which are responsible for cellular ATP production by oxidative phosphorylation. Energy production of mitochondria comes from the metabolism of glucose and fatty acids through a series of reactions ( Figure 1) . Pyruvate, the end-product of aerobic glycolysis, is derived partly from blood-borne glucose but mainly from endogenous glycogen. Once formed in the cell cytosol, pyruvate may be reduced to lactate, transaminated to alanine, or transported into the mitochondria where it undergoes oxidative decarboxylation to acetyl-coenzyme A (acetyl-CoA) catalyzed by the pyruvate dehydrogenase complex (PDHC). Long-chain fatty acids, after being activated to form fatty acyl-CoA in the cytosol, must be transferred across the inner mitochondrial membrane to be oxidized to acetyl-CoA. Acetyl-CoA then enters the citric acid cycle (Krebs cycle), which releases eight hydrogen molecules and produces carbon dioxide and water through oxidative phosphorylation. This process liberates energy along the respiratory chain, which receives energy-rich hydrogen atoms from nicotinamide adenine dinucleotide (NADH) or flavineadenine dinucleotide (FADH), produced mainly in the Krebs cycle and from fatty acid oxidation. Electrons from the hydrogen are passed between respiratory complexes in the chain and result in energy production.
Mitochondrial respiratory chain (RC) complex is a unique system in the cell coded by two genomes, known as the ABCB7 Z ATP-binding cassette, sub-family B (MDR/TAP), member 7; AGK Z acylglycerol kinase; ANT1 Z adenine nucleotide translocase 1 gene; C10orf2 Z chromosome 10 open reading frame 2; COX Z cytochrome c oxidase; DARS2 Z aspartyl-tRNA synthetase 2; DDP1 Z deafness dystonia peptide 1; DGUOK Z deoxyguanosine kinase; DLP1 Z dynamin-like protein-1; KIF5A Z kinesin family member 5; MFN2 Z mitofusin 2; MPV17 Z mitochondrial inner membrane protein; MRPS16 Z mitochondrial ribosomal protein S16; mtDNA Z mitochondrial DNA; nDNA Z nuclear DNA; ND Z NADH dehydrogenase; NDUFS Z NADH dehydrogenase (ubiquinone) Fe-S protein; NDUFV Z NADH dehydrogenase (ubiquinone) flavoprotein; np Z nucleopeptide; OPA1 Z optic atrophy 1; PDHC Z pyruvate dehydrogenase complex; PDSS Z prenyl (decaprenyl) diphosphate synthase; PEO1 Z C10orf2 encoding a mitochondrial helicase (Twinkle); POLG gene Z polymerase-gamma gene; PUS1 Z pseudouridylate synthetase-1; RARS2 Z arginyl-tRNA synthetase 2; RCC Z respiratory chain complex; RRM2B Z p53-dependent ribonucleotide reductase; SDHA Z succinate dehydrogenase complex, subunit A; SERAC1 Z serine active site containing 1; SLC25A3 Z solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3; SUCLA2 Z b-subunit of the adenosine diphosphate-forming succinyl-CoA-ligase; SUCLG1 Z alpha-subunit of GDP-forming succinyl-CoA-ligase; TAZ Z tafazzin; TK Z thymidine-kinase; TMEM70 Z transmembrane protein 70; TYMP Z thymidine phosphorylase; YARS2 Z tyrosyl-tRNA synthetase 2.
powerhouse system of the cell, where the energy production occurs through the oxidative phosphorylation pathway. The mitochondrial RC system is located in the mitochondrial inner membrane, organized in five enzymatic complexes (IeV), ubiquinone (or coenzyme Q10), and cytochrome c. Complexes I, III, and IV extrude protons from the mitochondrial matrix. Complex IV consumes oxygen to form water. Complex V couples ATP synthesis to proton reentry, which is powered by the electrochemical gradient. 48 Ultimately, the energy is stored as ATP. These assumptions are the basis for the biochemical evaluation of mitochondrial RC enzymes' activity.
The term "mitochondrial diseases" refers to a class of disorders characterized by an impairment of the mitochondrial RC, where most cellular ATP is generated.
Mitochondrial genetics
The human mitochondrial genome is a 16,569-bp doublestranded DNA circle that contains 37 genes, of which 13 genes encode subunits of the respiratory chain, and 22 tRNAs and two ribosomal RNA genes (12S and 16S) translate mtDNA. Each cell contains many mitochondria with 2e10 mtDNA molecules. The total mtDNA accounts for approximately 0.5% of the DNA in a nucleated somatic cell.
The 13 mitochondrial protein-coding genes contribute to the four enzyme components of the RC complexes required for oxidative phosphorylation: seven of them are subunits of complex I (NADH-ubiquinone oxidoreductase), one of complex III (ubiquinolecytochrome c oxidoreductase), three of complex IV (cytochrome c oxidase), and two of complex V (Hþ-translocating ATP synthase). All of the subunits of complex II (succinateeubiquinone oxidoreductase), the remaining subunits of the other mitochondrial RC complexes as well as the factors involved in mtDNA replication, transcription, and translation, are encoded by nuclear DNA (nDNA).
Mitochondrial genetics differ from Mendelian genetics in several fundamental aspects. First, mtDNA is maternally inherited because mitochondria derive solely from the oocyte. A normal cell has only a single mtDNA genotype and is therefore homoplasmic. However, if the genomes represent a mixture of a wild-type and a mutated-type, the cell genotype is heteroplasmic. The clinical pictures of mitochondrial diseases are determined by the proportion of normal-to-mutated genomes in the mitochondria. Once the proportion exceeds a theoretical threshold, the biological behavior of the cell will change. This minimum critical amount differs from tissue to tissue and different tissues may be variously affected by different combinations and to different degrees. In addition, mitotic segregation of the mitochondria influences the biological behavior governing the stochastic redistribution of wild-type and mutated genomes during mitochondrial and cell divisions. Thus, the concepts of threshold effect and mitotic segregation provide theoretical explanations for the variable phenotype expressions of the MDs.
The dual genetic control of the RC represents the ubiquitous nature of mitochondria. The mitochondrial metabolic pathway is under the control of not only the mitochondrial, but also the nuclear genomes, which are strictly coordinated to ensure the correct functioning of the mitochondrial machinery. To date, it has been established that 1500 nuclear-encoded proteins are targeted to the mitochondria. 49 Mutations in nDNA can affect: (1) components of RC subunits; (2) mitochondrial ancillary proteins involved in RC complexes formation, turnover, and function; (3) intergenomic signaling for mtDNA maintenance or expression; (4) biosynthetic enzymes for lipids or cofactors; (5) coenzyme Q; (6) mitochondrial trafficking or transport machinery; (7) mitochondrial biogenesis; or (8) apoptosis. 50 A brief summary of published genetic classification of MDs is shown in Table 1 . 49, 50 Primary mtDNA mutations may exhibit a maternal inheritance, or Mendelian traits that present with multiple somatic mtDNA alterations. In the case of Mendelian disorders, autosomal recessive, autosomal dominant, and X-linked patterns have all been observed. Recent studies have demonstrated that approximately 10e15% of MDs are caused by mutations in mtDNA, 48 and up to 25% of selected children with MDs are caused by mutations in nDNA 49 ; i.e., MDs in children result more often from nDNA mutations. In addition, it has been reported that > 200 nuclear-encoded genes have been linked to human disease. 49 Therefore, genetic diagnosis of MDs in infants and children is a difficult task due to the heteroplasmy of mtDNA mutations and the large number of nuclear genes involved in different tissues.
Clinical manifestations
MDs that result from diminishing ATP production cause clinical disorders. Several studies 51e53 showed clinical features in patients with MDs which support the maxim "any tissue and any signs at any age". 54 However, infants and children with MDs tend to have an acute onset of the clinical symptoms and courses compared with adults with MDs, who typically exhibit slow and/or progressive presentations. In general, the clinical spectrum is not limited to the neuromuscular system; indeed, a number of nonneuromuscular organs may exhibit symptoms and signs, such as the heart, eyes, ears, kidneys, endocrine glands, liver, bone marrow, and gastrointestinal tract. 42 The clinical manifestations of 103 pediatric patients with MDs in our case series, expanding data from the previous report, 42 are summarized in Table 2 . The commonest clinical manifestation was symptoms and signs of CNS (93/103; 90.3%). The CNS manifestations of MDs were variable, including seizures, developmental delay, altered level of consciousness, floppiness, spasticity, mental retardation, sucking difficulty, involuntary movement, headache, apnea, external ocular motility limitation, tremor, apneustic respiration, dystonia, stroke, sudden infant death syndrome, and/or hypoventilation. The second most common clinical features were ophthalmologic problems (37/103; 35.9%) and failure to thrive (37/103; 35.9%). The symptoms and signs of the ophthalmologic system included ptosis, retinitis pigmentosa, external ophthalmoplegia, visual loss, nystagmus, exotropia, blurred vision, visual field defect, strabismus, corneal clouding, and/ or optic nerve atrophy. The fourth most common clinical feature was cardiovascular system dysfunction (26/ Alpers' disease, 57 lethal infantile mitochondrial disease (LIMM), 59 , 60 Pearson's syndrome (PS), 58,70e72 KearnseSayre syndrome (KSS), 56 mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), 64 myoclonic epilepsy with ragged-red fibers (MERRF), 61, 62 neuropathy, ataxia, and retinitis pigmentosa (NARP), 67 mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), 65 chronic progressive external ophthalmoplegia (CPEO), 63 Leber's hereditary optic neuropathy (LHON), 66 and Barth syndrome (BTHS). 68 The patients who fulfilled the diagnostic criteria for MDs but not specific syndromes, were classified as having noncategorized or nonsyndromic MDs. 42 Recently published studies 42,51e53 show that pediatric patients with nonsyndromic MDs are not uncommon, and the clinical manifestations are nonspecific. 42, 73 Specific mitochondrial syndromes are easy to diagnose because each of them has its own clinical phenotypes. However, it is not easy to diagnose nonsyndromic MDs during the early stage of disease course due to the wide variety of clinical features. Thus, follow-up of clinical symptoms/signs in these patients is important.
Diagnostic approach of mitochondrial diseases

Diagnostic criteria
Different consensus diagnostic criteria for MDs in children are available. Major and minor criteria are usually based on clinical, biochemical, pathologic, and molecular findings.
In 1996, Walker et al 74 proposed diagnostic criteria for adults with respiratory chain disorders (Adult criteria; AC). In 2002, Bernier et al 75 suggested a modified version of the Adult criteria (Modified Walker criteria or Modified Adult Criteria; MAC) in order to improve the sensitivity and expand its use to include pediatric patients as well as adults. The diagnostic criteria of MDs were established on the basis of assigning major or minor criteria for clinical, pathological, enzymatic, functional, molecular, and metabolic parameters. Mitochondrial encephalomyopathies were categorized as definite, probable, or possible. A definite diagnosis is defined as fulfillment of either of two major criteria or one major criterion plus two minor criteria. A probable diagnosis is defined as either one major criterion and one minor criterion or at least three minor criteria. A possible diagnosis is defined as either a single major criterion or two minor criteria, one of which must be clinical.
In 2002, Wolf et al 76 proposed the consensus mitochondrial diagnostic criteria (MDC) scoring system for infants and children, which evaluates clinical features (I; maximum clinical score: 4 points) of muscle symptoms (IA; maximum score: 2 points), CNS abnormalities (IB; maximal score: 2 points), and multisystem involvement (IC; maximal score: 3 points), adding metabolic abnormalities and neuroimaging (II; maximum addition score: 4 points). Histologic anomalies (III) could increase the score with 4 points, leading to a maximum score of 12 points. Scores of 8e12, 5e7, 2e4, and 1 were defined as definite, probable, possible, or unlikely mitochondrial disorders, respectively. The MDC uses welldefined items (clinical, laboratory, pathologic, and biochemical) for scoring and dividing criteria into two subsets: general (clinical, metabolic, imaging, and pathologic) and biochemical. This allows a critical and independent evaluation for general features and for results of biochemical investigations, before combining the two. The advantages of MDC criteria are that the general criteria (without the histochemical part) allow preclassification of patients before a muscle biopsy is performed. If a patient with an undiagnosed disorder reaches the probable or definite general classification, a muscle biopsy may be strongly recommended.
The different consensus diagnostic criteria for MDs in children described above show how difficult it can be to diagnose MDs; that is, the diagnosis of MDs with certainty requires analysis from multiple perspectives.
Diagnostic tools 5.2.1. Blood laboratory investigation
Lack of a clinically pathognomonic hallmark frequently makes laboratory investigations necessary to confirm the diagnosis.
For basic laboratory investigations, blood lactate is used as a biochemical marker for the screening of MDs. The differential diagnosis of lactic acidosis includes physiological anaerobic exercise, systemic diseases that increase blood lactate levels, cerebral diseases that increase CSF lactate levels, metabolic diseases, poor collection technique, or poor sample handling. 77 However, blood lactate level is not always elevated in patients with MDs, and thus, normal serum lactic level does not exclude a mitochondrial Data are presented as n (%).
disorder. 42, 51 A glucose challenge test followed by successive blood lactate examinations, oral glucose lactate stimulation test (OGLST), is a better screening method than a single blood lactate test. 3, 11, 42 Lactic acidosis may be proportionate or disproportionate to the elevation of pyruvate based on the associated effect of the biochemical defect on the oxidationereduction potential. If the oxidationereduction potential is unaffected by the biochemical defect, the lactate and pyruvate elevations will be proportional and the lactate/pyruvate ratio will be normal. By contrast, if the oxidationereduction potential is disturbed by a primary defect involving the respiratory chain, the lactate values will be disproportionately elevated and the lactate/pyruvate ratio will be increased (> 25).
If available, CSF lactate, and pyruvate concentration should also be measured. It is useful to calculate a lactateto-pyruvate ratio because an elevated ratio suggests the possibility of a MD.
Metabolic survey
Lactic acidosis can be caused not only by intramitochondrial (primary) disorders, but also by extramitochondrial (secondary) disorders. The latter include defects of metabolic pathways for glycogen, gluconeogenesis, and organic acidemia. Thus, a metabolic screening with measurement of basic blood and urine analytes such as plasma ketone body (3-OH butyrate/acetoacetate) ratio, serum transaminase, plasma amino acid quantitation, tandem mass spectrometry (MS/MS), plasma acylcarnitine profile, and urinary organic acids, is helpful for differential diagnosis of MDs.
Imaging studies
The clinical diagnosis of MDs has been greatly improved by advances in neuroimaging technology. Brain magnetic resonance imaging (MRI) is sensitive to these diseases, especially in clinically phenotypic mitochondrial syndromes, including LS, MELAS, MNGIE, and KSS. In infants and children with nonsyndromic MDs, brain MRI can produce variable findings, from normal results to signal changes over the basal ganglia or brainstem. 43 MR spectroscopy (MRS) for detecting the concentration of a number of biochemical metabolites in vivo has been reported to be a useful tool in conducting differential diagnoses and for monitoring of MDs. 44, 78 5.2.4. Tissue biopsy and MRC enzymatic assay A muscle biopsy using light microscopic and electron microscopic examinations is an auxiliary diagnostic method of MDs. Morphological examinations include the modified Gomori trichrome staining for RRFs, ATPase staining for the assessment of myofibrillar integrity, muscle-type fiber predominance and distribution, and cytochrome c oxidase and succinate dehydrogenase staining for oxidative enzymes. RRFs showing on the modified Gomori trichrome stain may be noted in a minority of patients, especially in children aged < 3 years, 51 but our previous study showed the presence of RRF was not low in infants and children with MDs. 42 Electron microscopic examination of muscle cells may reveal abnormal mitochondrial configurations and/or subsarcolemmal abnormal mitochondrial accumulation in those patients. 42 In addition to morphological examinations, mitochondrial RC complex enzyme analysis of biopsied muscle or skin fibroblasts is helpful to confirm RC complex defects and provide a clue for determining causative nDNA mutations. All patients, prior to undergoing a muscle biopsy, should have a careful clinical and metabolic workup to detect the extent of organ involvement and metabolic disturbance.
Mitochondrial genetic testing
The confirmation of the MD diagnosis by molecular methods often remains a challenge because of the large number of known genes involved in mitochondrial energy production, the complexity of the two genomes, and the heteroplasmic proportions of pathogenic mtDNA in a patient. A molecular diagnostic approach for MDs has been proposed. 79 If the phenotype is suggestive of syndromic MDs, screening of common point mutations, common deletions in mtDNA or specific nDNA mutations is the first step. In cases where characteristic mitochondrial RC complex deficiencies and histochemical abnormalities are observed, direct sequencing of the specific causative nuclear genes can be performed on white blood cell DNA. Measurement of mtDNA content in affected tissues, such as muscle, also allows screening for mtDNA depletion syndromes. In selected cases testing negative, additional analyses can include whole mtDNA genome screening for the detection of rare and novel point mutations. As new nDNA mutations are constantly being discovered, clinicians may use next generation sequencing (NGS) for molecular analysis. Known causative genes of MDs will improve genetic counseling.
Diagnostic algorithm
As the clinical manifestations of MDs are variable, diagnosis of MDs is much more difficult compared with other diseases. Therefore, the author suggests an evaluation process for clinical physicians to diagnose MDs in clinical practice (Figure 2 ). Diagnostic workups for suspected MDs are a stepwise procedure. The first step comprises a comprehensive individual and family history, and clinical investigations in neurology, ophthalmology, otology, endocrinology, cardiology, gastroenterology, nephrology, hematology, and so on. Important instrumental procedures include basic chemical investigations of serum and urine, electrophysiological investigations, and neuroimaging studies. Based on the results, the probability for the presence of a MD can be assessed based on the Bernier diagnostic criteria. 75 In the second step, clinicians need to decide whether an individual clinical phenotype conforms to any of the syndromic MDs or is characteristic of nonsyndromic MDs. When the presentation is classic for specific mitochondrial syndromes, for example, LS, MELAS, MERRF, LHON, or KSS, appropriate mtDNA studies should be obtained first. When the clinical picture is classic for a nDNA inherited syndrome and the gene or the linkage is known, for example, MNGIE, Alper's disease, some LS, or BTHS, proceed with genetic studies. When the clinical picture is nonsyndromic but biochemical findings are highly suggestive of a MD, clinicians can consider proceeding with muscle and/or tissue biopsies, and/or measurement of mitochondrial RC enzymatic assays. By applying this approach, clinicians can use diagnostic criteria to obtain a more accurate diagnosis. If the diagnosis is still uncertain and difficult, it is necessary to follow up the clinical manifestations of the patients.
Diagnostic dilemma
Although different consensus diagnostic criteria have been proposed, an unresolved issue is the question of primary versus secondary RC involvement. A growing number of reports show RC involvement in other inborn errors of metabolism such as fatty acid oxidation disorder, thiamine-responsiveness megaloblastic anemia, and various neurodegenerative disorders of childhood. 76 Careful interpretation of laboratory results is needed as enzyme deficiencies found on RC testing may be indicative of the primary disease or be secondary to another primary pathological condition. The diagnosis of MDs should therefore be conducted with care, especially in infants and children.
Conclusion
The study of MDs is a challenging and rapidly evolving field of medicine. A single clinical feature or diagnostic criterion is rarely sufficient for the proper diagnosis of a MD. The current approach to diagnosing and classifying MDs incorporates clinical, biochemical, neuroradiological, pathologic, and molecular information. The confirmation or exclusion of MDs is therefore a major challenge for clinicians, especially in cases with nonspecific clinical phenotypes. Therefore, follow-up evaluations of clinical symptoms/signs and biochemical data are crucial.
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• Laboratory tests: CBC, electrolytes, ABG, blood sugar, blood ketone, ammonia, lactate, Ms/Ms assay, amino acids assays, UOA assay, etc.
• Specific examinations: Hearing test, ECG, EEG, echocardiography, fundus examination, NCV, evoked potentials, etc.
• Neuroimaging studies: Brain MRI and MRS, etc.
History taking, physical examinations, and neurological examinations
• Variable clinical manifestations, including unexplained multiorgan disorders • CNS symptoms and signs, including refractory seizures with a progressive encephalopathy or encephalomyopathy, etc.
• "Red flag" of extra-CNS symptoms and signs, including short stature, neurosensory hearing loss, progressive external ophthalmoplegia, pigmentary retinopathy, optic neuropathy, peripheral neuropathy, cardiomyopathy, cardiac arrhythmia, hepatopathy, renal tubular acidosis, etc.
• Family history of unexplained developmental delay, epileptic seizures, or early death, etc.
• Soft signs in maternal relatives, including short stature, migraine, deafness, and diabetes, etc. Figure 2 A diagnostic algorithm in infants and children with mitochondrial disease. ABG Z arterial blood gas; CBC Z complete blood cell count; CNS Z central nervous system; ECG Z electrocardiogram; EEG Z electroencephalography; MDs Z mitochondrial diseases; MRI Z magnetic resonance imaging; MRS Z magnetic resonance spectroscopy; Ms/Ms Z tandem mass spectrometry; mtDNA Z mitochondrial DNA; NCV Z nerve conduction velocity; nDNA Z nuclear DNA; NGS Z next generation sequencing; OGLST Z oral glucose lactate stimulation test; S/S Z symptoms and signs; UOA Z urinary organic acids.
